Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Navrattan R. Munjal | Chairman & MD | 30.31M | -- | 1952 |
| Mr. Himanshu Jain BCom | Joint MD & Whole Time Director | 37.88M | -- | 1982 |
| Mr. Rishav Mehta | Executive Director | 15.16M | -- | 1991 |
| Mr. Sahil Munjal | President of Operations & Special Assignments and Executive Director | 17.91M | -- | 1980 |
| Mr. Gagan Aggarwal | Chief Financial Officer | -- | -- | -- |
| Ashok Kothari | General Manager of Information & Technology | -- | -- | -- |
| Mr. Pardeep Verma | VP of Corporate Affairs, Compliance Officer & Company Secretary | -- | -- | -- |
| Varun Chhabra | Senior Vice President of Marketing | -- | -- | -- |
| Akashdeep Sharma | Group HR Head | -- | -- | -- |
Ind-Swift Laboratories Limited
- Sector:?
- Healthcare
- Industry:? Drug Manufacturers - Specialty & Generic
- Full Time Employees:?
- 47
Description
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is headquartered in Manimajra, India.
Corporate Governance
Upcoming Events
November 5, 2024 at 10:59 AM UTC - November 9, 2024 at 12:00 PM UTC
Ind-Swift Laboratories Limited Earnings Date
Recent Events
September 20, 2011 at 12:00 AM UTC
Ex-Dividend Date